FDA draft guidance on early-phase solid-tumour INDs: comments due 11 January 2027

What happened

FDA has issued a draft guidance titled Early-Phase IND Protocol Recommendations for Solid Tumors. The Federal Register notice of availability is dated 12 November 2026, and FDA's own guidance page was listed two days earlier. According to the records, the draft sets out recommendations for first-in-human trials and for trials of products with limited human experience. It is an Oncology Center of Excellence document. It explicitly excludes haematologic malignancies. Comments are open until 11 January 2027.

The records do not describe the document's substantive recommendations. We do not yet know, from the material available to us, how it treats dose escalation, starting-dose selection, cohort expansion, eligibility, monitoring or any other protocol element. Teams should read the full text before drawing conclusions about what changes in practice.

Why it matters

Early-phase oncology protocols are where many sponsors first meet FDA review of a new product. A guidance aimed specifically at first-in-human and limited-experience solid-tumour protocols signals what the agency's oncology reviewers want to see at that stage. It also gives sponsors a reference point for pre-IND discussions.

The scope is a practical filter. Sponsors running haematologic programmes cannot assume the recommendations apply to them, and the exclusion is stated outright. Sponsors with solid-tumour programmes, particularly novel agents with little or no human data, are the clear target audience.

Regulatory context

Draft guidance is not final and does not bind FDA or sponsors. It reflects the agency's current thinking and is published for public comment. Once the comment period closes, FDA reviews submissions and may revise the text before issuing a final version. The records do not say when a final version might appear, and that timing is not yet known.

The comment window therefore matters more than it might seem. Sponsors, CROs, academic investigators and patient groups can use it to flag recommendations that are hard to operationalise, ask for clarification, or point out gaps. A comment grounded in concrete protocol experience tends to be more useful to reviewers than a general statement of support or objection.

One housekeeping point: the two FDA-sourced records carry different agency labels, with one attributed to CBER in our feed and the other to FDA generally. Both describe the same draft and the same 11 January 2027 deadline. Teams should work from the Federal Register notice and FDA's guidance page rather than secondary listings.

Who is affected, and how the wider news flow fits

The direct audience is regulatory affairs and clinical operations staff at sponsors planning or running first-in-human solid-tumour studies, plus the CROs and sites that execute them. Protocol authors and medical monitors will want to compare current templates with the draft.

Other items in this week's news flow are only loosely connected. Zentalis Pharmaceuticals reported Q3 2026 results and said it is eyeing FDA talks on accelerated approval for azenosertib after a DENALI readout expected in the first half of 2027. It also said Part 2c enrolment completes in November and that its cash runway extends into the first half of 2028. The records do not say whether the guidance bears on that programme, and we do not draw that link. The item is a reminder that sponsors build timelines around FDA interactions, and that guidance published mid-programme can shape those conversations.

Two device field safety notices are unrelated to the guidance. BfArM published an urgent notice from BD Switzerland Sarl on the BD Connecta infusion connector, but the defect, affected lots and required actions appear only in the manufacturer's attached advisory. The Dutch inspectorate IGJ published a notice on Boston Scientific's OptiCross intravascular ultrasound catheters, where the manufacturer is revising instructions for use after reports of air embolism and repeated flushing. Neither record links these devices to oncology trials. They are relevant only for sites that use such devices in any study, and the details sit in the manufacturers' notices.

What to watch

The first marker is the 11 January 2027 comment deadline and any public comments that surface before then. After that, watch for whether FDA publishes a final guidance and how far it departs from the draft. Also watch whether the agency says anything about haematologic malignancies, which are outside this document's scope. The records give no indication either way.

For sponsors with first-in-human solid-tumour protocols already in preparation, the main question is timing. Teams will need to decide whether to align protocols with the draft now or wait for the final text. That is a judgement for each sponsor's regulatory team, ideally informed by direct FDA feedback.